Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer

Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer

IntroductionMetastatic castration-resistant prostate cancer (mCRPC) is an aggressive disease with a poor prognosis and few therapeutic options. In recent years, 177Lu-PSMA, a novel radioligand therapy, has shown promising results in patients who have failed conventional therapies. However, around 30...

Full description

Saved in:
Bibliographic Details
Main Authors: Hugo Peslier, Valérie Seegers, Pierre-Alban Dufour
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Medicine
Subjects:
177Lu-PSMA
mCRPC
predictive factors
therapeutic response
SULmax
total tumor volume
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1538507/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items